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in any medium, provided the original work is properly citeMetastatic spread is the single-most powerful predictor of poor outcome in Ewing
sarcoma (ES). Therefore targeting pathways that drive metastasis has tremen-
dous potential to reduce the burden of disease in ES. We previously showed that
activation of the ERBB4 tyrosine kinase suppresses anoikis, or detachment-
induced cell death, and induces chemoresistance in ES cell lines in vitro. We
now show that ERBB4 is transcriptionally overexpressed in ES cell lines derived
from chemoresistant or metastatic ES tumours. ERBB4 activates the PI3K-Akt
cascade and focal adhesion kinase (FAK), and both pathways contribute to
ERBB4-mediated activation of the Rac1 GTPase in vitro and in vivo. ERBB4
augments tumour invasion and metastasis in vivo, and these effects are blocked
by ERBB4 knockdown. ERBB4 expression correlates significantly with reduced
disease-free survival, and increased expression is observed in metastatic com-
pared to primary patient-matched ES biopsies. Our findings identify a novel
ERBB4-PI3K-Akt-FAK-Rac1 pathway associated with aggressive disease in ES.
These results predict that therapeutic targeting of ERBB4, alone or in combi-
nation with cytotoxic agents, may suppress the metastatic phenotype in ES.INTRODUCTION
Ewing sarcoma (ES) is the second most common bone tumour in
children and adolescents (Riggi & Stamenkovic, 2007). These
tumours are characterized by etiologic gene fusions of EWS to
different members of the ETS transcription factor family, and the
expression of chimeric EWS–ETS fusion proteins such as EWS-ndon, UK
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d.FLI1 and EWS–ERG are pathognomonic of the disease (Toomey
et al, 2010). Multi-modality therapy has greatly improved the
outcome for ES patients, and those with localized disease at
diagnosis have 5-year survival rates approaching 70% (Damron
et al, 2007). However, patients with metastatic disease have
a dismal outcome with 5-year survival rates of only 15–25%
(Linabery & Ross, 2008). In fact, the presence of metastatic
disease remains the single-most powerful predictor of outcome
in ES (Bernstein et al, 2006). Patients with early relapse
following therapy have a similarly poor outcome, most
commonly due to the development of pulmonary or bone
metastases. Numerous studies have begun to dissect mecha-
nisms of transformation by EWS–ETS fusion oncoproteins, which
function as chimeric transcription factors (Riggi & Stamenkovic,
2007). While revealing important insights into disease patho-
genesis and establishing new molecular tools for diagnosis,
these findings have not significantly impacted on treatment and
outcome. First, EWS–ETS chimeras are challenging to drug,
although potential downstream pathways may be more
tractable for targeting (Braunreiter et al, 2006; Prieur et al,s is an open access article under
se, distribution and reproduction
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10882004; Smith et al, 2006). Second, EWS–ETS proteins are
expressed in both localized and metastatic disease, and thus do
not on their own account for metastatic behaviour (Ginsberg
et al, 1999). Thus, there is an urgent need to identify specific
biologic drivers orchestrating the process of metastasis in ES,
and to evaluate novel therapeutics potentially targeting the
involved pathways, either alone or in combination with
standard-of-care chemotherapeutic agents.
There are surprisingly few reports relating to molecular
mediators of metastasis in ES (Bennani-Baiti et al, 2010;
Krishnan et al, 2006; Sainz-Jaspeado et al, 2010). We previously
focused on the capacity of ES cells to suppress anoikis, or
programmed cell death after detachment from the extracellular
matrix (Frisch & Francis, 1994), to screen for candidate
metastasis drivers in ES. Resistance to anoikis is critical for
cancer cells to survive under anchorage independent conditions
such as the circulation or the lymphatics, prior to establishment
of overt metastases (Simpson et al, 2008). To model anoikis
resistance in vitro, cell lines are cultured in suspension rather
than conventional monolayers. In vitro survival under such
conditions correlates strongly with in vivo metastasis of the
same cell lines in immunodeficient mice (Douma et al, 2004).
We previously found that TC32 and TC71 ES cell lines survive as
multicellular spheroids in non-adherent suspension cultures
(Kang et al, 2007; Lawlor et al, 2002). This correlated with
increased activation of the PI3 kinase (PI3K)-Akt pathway but
not Ras-ERK1/2, and reduced sensitivity to multiple cytotoxic
agents compared with conventional monolayer cultures (Kang
et al, 2007). In addition, the ERBB4 (HER4) receptor tyrosine
kinase, a member of the epidermal growth factor receptor
(EGFR) family, was preferentially activated under anchorage
independent conditions. This was not associated with changes
in ERBB4 protein expression, but correlated with both PI3K-Akt
activation and chemoresistance in these cell lines (Kang et al,
2007). These findings suggest a potential link between ERBB4
and advanced disease in ES. However, a role for ERBB4 in
metastatic progression has not been previously reported.
We now report a novel function for ERBB4 as a metastatic
driver in ES. ERBB4 is overexpressed in ES cell lines derived
from advanced tumours as well as in human metastatic ES
lesions, and leads to activation of PI3K-Akt, focal adhesion
kinase (FAK), and the Rac1 GTPase, a well-established mediator
of cell migration and invasion. ERBB4 expression is directly
correlated with increased in vivo metastasis of ES cell lines,
and is upregulated in metastatic ES tumours. These studies
provide new insights into the biology of ERBB4 in ES, and
independently validate ERBB4 as a metastasis associated factor
in this disease.RESULTS
ERBB4 is overexpressed in cell lines derived from ES
To screen for potential markers of aggressive disease in ES, we
compared gene expression profiles (GEPs) in CHLA-10 versus
CHLA-9 ES cell lines. The latter was established from an
untreated primary ES at the time of diagnosis, while the CHLA- 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.10 cell line was established from a recurrence in the same
patient after four cycles of induction chemotherapy with
cisplatin, doxorubicin, cyclophosphamide and etoposide (Batra
et al, 2004). GEPs generated using Affymetrix Human Exon
(HuEx) arrays revealed a number of cell line specific differences.
Forty-six genes were found to be significantly differentially
expressed (with at least sevenfold altered expression), with
40 genes significantly upregulated and 6 genes significantly
downregulated in CHLA-10 compared to CHLA-9 cells
(Supporting Information Fig S1A). The full list of all genes,
their encoded proteins, and known functions and relation to
cancer can be found in Supporting Information Table S1. Among
the upregulated genes in our dataset, transcripts encoding ERBB4
were 10-fold increased in CHLA-10 compared to CHLA-9 cells
(Fig 1A; p¼ 0.015). We focused on ERBB4, given the previous
link between activation of this tyrosine kinase and anoikis
suppression in ES (Kang et al, 2007). Western blotting demon-
strated dramatically higher expression of the full-length 180 kDa
ERBB4 species in CHLA-10 compared to CHLA-9 cells under
conventional monolayer (M) culture conditions, which was
further enhanced in non-adherent suspension (S) cultures of the
same cell lines (Fig 1B). We then tested whether the observed
ERBB4 induction was transcriptionally regulated. ERBB4 tran-
scripts are known to undergo alternative splicing to generate
different juxtamembrane (JM-a and JM-b) and cytoplasmic (CYT-
1 and CYT-2) isoforms of full-length ERBB4 (Junttila et al, 2003).
We therefore used previously described TaqMan quantitative RT-
PCR (qRT-PCR) assays (Junttila et al, 2003) to specifically identify
ERBB4 splice forms that are expressed in CHLA-9 and CHLA-10
cells. This revealed increased expression of JM-a/CYT-1 and
JM-a/CYT-2 transcripts in CHLA-10 compared to CHLA-9 cells,
and both were increased in S compared to M cultures for each cell
line (Fig 1C); there was no evidence for expression of the JM-b
splice form (data not shown). We then extended this analysis to a
larger panel of ES cell lines. TaqMan qPCR revealed variable
JM-a/CYT-1 and JM-a/CYT-2 ERBB4 transcript expression in M
cultures, which was generally enhanced in S cultures of the same
cell lines (Fig 1D). TC71 only showed modest increase in mRNA
levels when cultured in suspension. Again the JM-b splice form
was not observed in any of these cell lines (Fig 1D). Immunoblot-
ting confirmed that ERBB4 protein levels correlated with increased
JM-a/CYT-1 and JM-a/CYT-2 transcript expression (Fig 1E). The
highest overall expression was observed in CHLA-10, SK-N-MC,
COG-E-352, CHLA-25 and TC71 cell lines. Each of these cell lines
was derived from post-chemotherapy ES tumours (Supporting
Information Table S2), further highlighting a link between ERBB4
induction and aggressive disease in ES.
Processing of the full-length JM-a/CYT-1 or JM-a/CYT-2
isoforms by tumour necrosis factor-a-converting enzyme
(TACE) and g-secretase is known to generate an 80 kDa (p80)
ERBB4 soluble intracellular fragment that undergoes nuclear
translocation (Lee et al, 2002; Rio et al, 2000); p80 expression is
associated with poor survival in breast cancer models (Junttila
et al, 2005). However, we failed to identify differences in the
ERBB4 intracellular form in CHLA-9 versus CHLA-10 cell lines;
moreover, no differences in nuclear ERBB4 expression were
observed following subcellular fractionation, even after treat-EMBO Mol Med (2013) 5, 1087–1102
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Figure 1. ERBB4 protein is overexpressed in cell lines derived from chemoresistant or metastatic ES.
A. Heat-map reveals increased ERBB4 expression across most exons in CHLA-10 compared to CHLA-9 ES cells; data show n¼ 5 repetitions.
B. ErbB4 expression levels were analyzed byWestern blot in CHLA-9 and CHLA-10 cells cultured under M or S conditions. Actin was used as a loading control. One
of three representative experiments is shown.
C. ERBB4 isoforms expression was analyzed by qPCR in CHLA-9 and CHLA-10 cells grown as M or S, using ERBB4 TaqMan probes. Graphs represent mean SD of
three independent experiments with two replicates each (p< 0.05; p<0.01; p< 0.005). Specific numerical p-values for these and all subsequent
experiments are itemized in Supporting Information Table S6.
D. ERBB4 isoforms expression in samples from eight ES cell lines grown asM or S was evaluated by TaqMan qPCR. Top depicting JM-a and JM-b, and bottom CYT-1
and CYT-2 expression; n¼ 3 in duplicate.
E. ERBB4 expression levels were analyzed by Western blotting in a panel of ES cell lines. Actin was used as a loading control. One of three representative
experiments is shown.ment with the phorbol ester, PMA, known to activate TACE
(Zhang et al, 2001) (data not shown). Genome-wide copy
number analysis using Affymetrix SNP6.0 arrays failed to reveal
ERBB4 copy-number aberrations in any of the cell lines analyzed
(Supporting Information Fig S1B). Moreover, sequencing of
ERBB4 in CHLA-9 and CHLA-10 cells did not detect any ERBB4EMBO Mol Med (2013) 5, 1087–1102 mutations (data not shown). Therefore the mechanism of ERBB4
mRNA induction in ES cell lines remains unknown. Taken
together, our data indicate full-length ERBB4 protein is over-
expressed in cell lines derived from post-chemotherapy ES, and
that this occurs through transcriptional upregulation of ERBB4
JM-a/CYT-1 and JM-a/CYT-2 splice forms.2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 1089
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1090ERBB4 activates the PI3K-Akt pathway under diverse forms of
cell stress
CYT-1 contains a PI3K binding motif, which is required for
PI3K-Akt activation and regulation of cell survival by ERBB4
(Elenius et al, 1999). We therefore assessed if elevated ERBB4
expression is associated with PI3K-Akt stimulation. Indeed,
increased ERBB4 expression correlated with augmented Akt
activation, as phospho-Thr-308 and Ser-473 Akt levels were
both dramatically increased in CHLA-10 compared to CHLA-9
cells, particularly in S cultures (Fig 2A), which correlates with
our previous findings in ES cell lines (Kang et al, 2007). To
validate the contribution of ERBB4 to the prosurvival PI3K-Akt
pathway, we used short hairpin RNAs (shRNAs) for stable
ERBB4 knockdown (kd). Two independent shRNA targeting
constructs (designated 1410 and 1411) strongly downregulated
ERBB4 protein expression in both M and S cultures of CHLA-10
cells (Fig 2B). These shRNAs also dramatically reduced
ERBB4 tyrosine phosphorylation (Tyr-P) levels in CHLA-10 cells,
but did not affect Tyr-P of other EGFR family proteins, as assessed
using R&D Human phospho-RTK Proteome arrays (Supporting
Information Fig S2A and S2B). ERBB4 kd strongly reduced Akt
activation in both M and S cultures of CHLA-10 cells, but
particularly in the latter (Fig 2B), as well as in S cultures of
two other high ERBB4-expressing ES cell lines, CHLA-25 and
SK-N-MC (Fig 2C). Rescue of ERBB4 expression in 1410 or 1411
kd cells using an ERBB4 construct engineered to be resistant to
knockdown through silent mutations in the ERBB4 shRNA
targeting region restored ERBB4 expression and Akt activation in
ERBB4 kd cells (Supporting Information Fig S2C), validating the
specificity of these shRNAs. ERBB4 kd significantly increased
apoptosis in the high ERBB4-expressing ES lines, CHLA-10,
CHLA-25 and SK-N-MC, as demonstrated by increased cleaved
PARP (c-PARP) levels (Supporting Information Fig S2D).
Induction of apoptosis was additionally confirmed by propidium
iodide staining and FACS analysis in CHLA-10 cells grown as M
and S cultures (Supporting Information Fig S2E; p< 0.005). We
then assayed ES cells for expression of known ERBB4 ligands
(Revillion et al, 2008), revealing variable expression of heparin
binding EGF-like growth factor (HB-EGF), neuregulin 1 and 2
(NRG-1 and NRG-2), and amphiregulin (ARG) (Supporting
Information Fig S2F), while betacellulin (BTC) was not expressed
(data not shown). Treatment of CHLA-10 S cultures with HB-EGF,
NRG-1 or NRG-2 did not further increase ERBB4 Tyr-P
(Supporting Information Fig S2G), or Akt Ser-473 phosphoryla-
tion, (Supporting Information Fig S2H) since ERBB4 and Akt were
already strongly activated under these conditions. Together, these
findings show that high ERBB4 protein expression is associated
with PI3K-Akt activation and increased survival in ES cell lines.
Since detachment from the extracellular matrix, such as
during enforced growth in suspension, is a form of cell stress
(Ng et al, 2012), we wondered if ERBB4 induction might be
part of a more generalized stress response. We therefore tested
if ERBB4 expression is also induced under a second form of
prototypical cell stress, namely serum starvation (SS). Indeed,
compared to M cultures, ERBB4 protein expression was further
upregulated under SS conditions in CHLA-10, CHLA-25 and
SK-N-MC high ERBB4-expressing ES cell lines, which strongly 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.correlated with increased Akt activation (Fig 2D). ERBB4 kd
almost completely blocked Akt activation under SS conditions in
each cell line (Fig 2E). Low ERBB4-expressing CHLA-9 ES cells
were then transduced with lentiviral constructs encoding full-
length ERBB4 or with control vector (pLEOC) alone, and cells
were grown under M, S or SS conditions as above. ERBB4
overexpression in these cells strongly activated Akt in each
culture condition (Supporting Information Fig S2I), confirming a
direct correlation between ectopic ERBB4 expression and Akt
activation in ES cells. Taken together, these findings indicate
that ERBB4 overexpression in ES cells regulates the PI3K-Akt
pathway under diverse forms of cell stress.
ERBB4 increases migration and invasion of ES cell lines
in vitro
Since increased ERBB4 expression was observed in ES cell lines
derived from post-chemotherapy ES, we tested whether this
kinase might also regulate migration and invasion of ES cells, two
essential components of the metastatic process. Using scratch
assays we found that high ERBB4-expressing CHLA-10 cells
migrated significantly faster than low-expressing CHLA-9 cells,
but this was markedly reduced in CHLA-10 1410 and 1411 ERBB4
kd cells (Fig 3A and B and Supporting Information Fig S3A;
p< 0.005). Lapatinib (http://www.cancer.gov/cancertopics/
druginfo/fda-lapatinib), a pan-ERBB inhibitor that decreased
ERBB4 Tyr-P in CHLA-10 cells (Supporting Information Fig S3B),
also significantly reduced ES cell migration, but to a lesser degree
than ERBB4 kd (Supporting Information Fig S3A). Invasive
capacity of metastatic ES cell lines with or without ERBB4 kd was
next examined using Matrigel-coated Boyden chambers. Cell
invasion was enhanced in CHLA-10 compared to CHLA-9 cells,
and again was significantly reduced by ERBB4 kd in each high
ERBB4-expressing cell line tested, CHLA-10, SK-N-MC and
CHLA-25 (Fig 3C–E). Differences in cell migration/invasion were
not due to reduced cell survival following ERBB4 kd, since the rate
of cell death over the time-course of the experiments (16–24 h)
was minor and accounted for only 5–15% of cell death in all
three lines analyzed (Supporting Information Fig S3C). Cell
invasion was rescued in ERBB4 kd cells transduced with non-
targeting ERBB4 constructs (Supporting Information Fig S3D),
further supporting the specificity of the ERBB4-mediated
invasive phenotype. ERBB4 overexpression in low ERBB4-
expressing CHLA-9 and TC32 ES cell lines also variably but
significantly increased invasion (Fig 3F; p< 0.05–0.005) and
migration (Supporting Information Fig S3E; p< 0.05–0.005).
These data indicate that ERBB4 overexpression alone increases
in vitro markers of aggressive behaviour in ES cells.
ERBB4 regulates Rac1 GTPase activity and cell spreading in
ES cell lines
To evaluate how ERBB4 enhances cell motility, we analyzed
members of the Rho GTPase family, which control dynamic
reorganization of the actin cytoskeleton to facilitate migratory
and invasive capacity (Stonecypher et al, 2006), in CHLA-10
versus CHLA-9 cell lines. Using affinity-based pull-down assays,
there was no evidence for RhoA activation in either cell line
(data not shown). Similarly, Cdc42 was not significantlyEMBO Mol Med (2013) 5, 1087–1102
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Figure 2. ERBB4 regulates PI3K-Akt in metastatic ES cell lines under diverse forms of cell stress.
A. Akt phosphorylation on Ser-473, Thr-308 or total Akt expression levels were evaluated by immunoblotting in CHLA-9 and CHLA-10 cells grown under M or S
conditions. Blots are representative of n¼3 independent experiments.
B,C. Targeting ERBB4 with 1410 and 1411 shRNA constructs reduced Akt phosphorylation in CHLA-10, CHLA-25 and SK-N-MC metastatic ES cells. One of three
representative experiments is shown.
D. Metastatic ES cell lines were growth as monolayer in serum-stimulated (M), serum-starved (SS) or spheroid (S) conditions for 24 h. ERBB4, p-Akt and total Akt
levels were evaluated by Western blot; n¼3 independent experiments.
E. ERBB4 kd reduced Akt activation in metastatic ES cell lines growth as M or SS conditions; n¼ 3 independent experiments.
EMBO Mol Med (2013) 5, 1087–1102  2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 1091
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Figure 3. Knockdown of ERBB4 impairs migration and invasion in cell lines derived from chemoresistant or metastatic ES.
A. Confluent monolayers of CHLA-9 and CHLA-10 ES cells transduced with 1410 and 1411 ERBB4 shRNA constructs were wound-scratched and allowed to
migrate for 30 h. The graph shows migration distance vs. time values SD of six independent experiments.
B–E. Uncoated (B), or Matrigel-coated transwells (C–E) were used to analyze the contribution of ERBB4 to B, the cell migration, and C–E, invasion processes in
control, or in ERBB4 kd CHLA-9, CHLA-10, SK-N-MC and CHLA-25 cells. Graphs represent mean SD of four independent experiments; p<0.005.
F. Overexpression of ERBB4 in CHLA-9 and TC-32 ES cells significantly increases cell invasion; n¼ 3, p<0.05, p<0.005.
1092activated in either M or S cultures of CHLA-9 and CHLA-10 cells
(Fig 4A, right panels). However, while Rac1 GTPase activity was
minimal in CHLA-9 and CHLA-10 M cultures (Fig 4A, left
panels), Rac1 activity was significantly increased in S compared
to M cultures of CHLA-10 cells (Fig 4A; p< 0.05). Moreover,
activation was abrogated in ERBB4 kd CHLA-10 cells in
suspension (Fig 4A). We next examined the contribution of
ERBB4 to cell spreading, known to be regulated by Rac1 and
Cdc42 Rho GTPases (Price et al, 1998). Using TRITC-phalloidin
staining as previously described (Price et al, 1998), we observed
that by 2 h after seeding,90% of CHLA-9 cells remained round,
in striking contrast to CHLA-10 cells, of which 80% showed
morphologic features of cell spreading (Fig 4B and C; p< 0.005). 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.Cell spreading led to marked Rac1 activation in CHLA-10 cells
but not in CHLA-9 cells, while Cdc42 was not active in either
cell line (Fig 4D). ERBB4 kd significantly reduced spreading
by 70% in CHLA-10 cells (Fig 4C; p< 0.005), and almost
completely blocked Rac1 activation (Fig 4D; see 1410 and
1411 lanes; p< 0.05), reducing levels to those of CHLA-9 cells.
We next assessed Rac1 GTPase activity in CHLA-9 cells
overexpressing ERBB4 (CHLA-9/ERBB4). CHLA-9/ERBB4 cells
showed a modest but reproducibly significant increase in
Rac1 activation compared to vector control CHLA-9 cells,
both in S cultures (Fig 4E; p< 0.05) and during cell spreading
(Fig 4F; p< 0.05). These data provide compelling evidence
that ERBB4 specifically activates Rac1 during anchorageEMBO Mol Med (2013) 5, 1087–1102
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Figure 4. ERBB4 regulates Rac1 GTPase activity through PI3K and FAK downstream pathways.
A. Rac1 and Cdc42 GTPase activities were measured by pull-down assays in CHLA-9 and CHLA-10 Scramb, or ERBB4 kd cells growth as M or S. Data shown are
representative of n¼3 experiments; p<0.05; p< 0.01; p< 0.005.
B. Phalloidin (red) and Hoechst nuclear staining (blue) of CHLA-9, CHLA-10 and ERBB4 kd CHLA-10 cells are shown.
C. Graph shows quantification of cell spreading; at least 25 cells were scored per condition. Values represent percentage of the mean SD; n¼3, p< 0.005.
D. Active Rac1 and Cdc42 (GTP-bound) levels were evaluated in control CHLA-9 and CHLA-10 cells, or in CHLA-10 ERBB4 kd cells 2 h after spreading assays. Rac1
and Cdc42 from total lysates were used as loading controls. Data shown are representative of three independent experiments; p< 0.05.
E,F. GTP-bound Rac1 levels were evaluated by pull-down assays in CHLA-9 control or CHLA-9/ERBB4 cells, and in CHLA-10 cells treated with different inhibitors.
Cells were growth under: (E) anchorage independent (S), or (F) cell spreading conditions. Rac1 from total lysates was used as a loading control. Graphs
represent mean SD of three independent experiments; p< 0.05, p< 0.005.
G. Total p-Tyr and FAK Tyr397 phosphorylation were assessed by immunoprecipitation in CHLA-9, CHLA-9/ERBB4, CHLA-10 and CHLA-10 ERBB4 kd cells, during
cell spreading assays. Lysates were immunoprecipitated for endogenous FAK, and immunoblotted with p-Tyr, FAK Tyr397 or FAK Abs. One of three
representative experiments is shown.
EMBO Mol Med (2013) 5, 1087–1102  2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 1093
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1094independent growth and cell spreading, in keeping with the
ability of ERBB4 to enhance invasiveness of ES cells.
ERBB4 regulates Rac1 GTPase activity through PI3K-Akt and
FAK pathways
In addition to specific guanine nucleotide exchange factors (GEFs),
Rac1 activity is also regulated by PI3K (Marcoux & Vuori, 2003)
and FAK (Chang et al, 2007). CHLA-10 cells were incubated with
the LY-294002 PI3K inhibitor, two FAK inhibitors, FAKinh14 or
FAKinhII, and the U0126 MEK inhibitor, as described in the
Materials and Methods Section. Inhibition of Akt, ERK1/2 and FAK
phosphorylation was confirmed using phospho-specific antibodies
(Supporting Information Fig S4A). While U0126 had no effect
on Rac1 activation, both LY294002 and FAKinh14 or FAKinhII
strongly blocked Rac1 GTPase activity in CHLA-10 cells under S
conditions (Fig 4E) or during cell spreading (Fig 4F). Reduced Rac1
activation following treatment with the different inhibitors was not
due to reduced cell survival (Supporting Information Fig S4B).
These data strongly support roles for both PI3K and FAK in
regulating Rac1 activation in metastatic ES cells.
To further explore potential links between ERBB4 and
FAK activation in ES cells, we immunoprecipitated FAK and
immunoblotted for total Tyr-P and FAK Tyr-397 phosphorylation
(as markers of FAK activation) in CHLA-9, CHLA-9/ERBB4,Figure 5. ERBB4 regulates cell migration and invasion through PI3K and FAK
A,B. The contribution of PI3K and FAK to the cell migration, and invasion proces
LY294002, and FAKinhII or FAKinh14 inhibitors. Graphs represent mean S
C. Knockdown of Rac1 and Akt, or transfection with Rac1 or Akt DN constructs re
n¼ 3 experiments; p<0.01, p<0.005.
 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.CHLA-10 and CHLA-10 ERBB4 kd cells. CHLA-10 displayed
significantly higher FAK activity compared to CHLA-9 cells
(Fig 4G; Supporting Information Fig S4C, p< 0.005), and ERBB4
overexpression in CHLA-9 cells moderately increased FAK
activation compared to CHLA-9 control cells (Fig 4G; Supporting
Information Fig S4C). ERBB4 kd significantly reduced both total
Tyr-P and Tyr-397 phosphorylation of FAK in CHLA-10 cells
(Fig 4G; Supporting Information Fig S4C, p< 0.05), supporting
a role for ERBB4 in regulating FAK activity in ES. Notably,
LY294002 had no apparent effects on FAK activation, and
FAK inhibitors only partially reduced Akt phosphorylation
(Supporting Information Fig S4A); therefore the interplay
between these pathways remains unclear.
Finally, we assessed effects of PI3K and FAK inhibition on
ES cell migration and invasion. Inhibition of either PI3K or FAK
moderately but significantly reduced migration and strongly
inhibited invasion in CHLA-10 cells in vitro (Fig 5A and B).
We then tested whether downstream effectors of PI3K and FAK,
namely Akt and Rac1, were involved in ERBB4 effects on cell
motility. We therefore performed siRNA knockdown of Akt 1
and 2 or Rac1 in CHLA-10 cells, as well as expression of
dominant negative Akt (Zhang et al, 2003) or Rac1 constructs
(Nobes & Hall, 1999). As clearly shown in Fig 5C, both
approaches provide compelling evidence that reducing Akt orpathways.
ses was analyzed in control CHLA-10 cells, or in CHLA-10 cells treated with
EM of three independent experiments; p< 0.05, p< 0.005.
ducedmigration and invasion in CHLA-10 cells. Graphs represent mean SD of
EMBO Mol Med (2013) 5, 1087–1102
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invasion of high ERBB4 expressing CHLA-10 cells. Together,
these data indicate that ERBB4 regulates Rac1 GTPase activity
and ES cell migration and invasion through both PI3K and FAK
pathways.
ERBB4 increases ES metastasis formation in vivo
The above studies predict that ERBB4 may regulate ES metastasis
in vivo. To test this we used the previously described mouse renal
subcapsular implantation (SCI) model (Cheng et al, 2010). This
model exhibits macroscopic, high-volume metastases of diverse
human tumour cell lines more rapidly than most subcutaneous or
orthotopic models, likely due to high vascularization of the renal
subcapsule graft site (Nakamura et al, 2011; Watahiki et al, 2011).
We adapted the SCI model to monitor growth of human ES cell
lines in vivo, as described in the Materials and Methods Section. As
shown in Supporting Information Fig S5A, both scrambled control
CHLA-10 and ERBB4 kd cells formed large tumours under the
renal capsules of implanted mice with the morphologic features of
ES, and no differences in tumour sizes were observed (data not
shown). However, CHLA-10 control cells demonstrated highly
infiltrative borders with direct invasion into adjacent normal
kidney (Fig 6A, arrows), while CHLA-10 ERBB4 kd cells
exclusively grew with so-called ‘‘pushing’’ non-invasive borders
into adjacent normal kidney (Fig 6A, arrowheads). ERBB4
knockdown tumours also showed extensive areas of necrosis
(Supporting Information Fig S5A; see arrows). Moreover, while
75% of mice implanted with scrambled control CHLA-10 cells
developed lung metastases, the rate of metastatic spread to lungs
in mice implanted with CHLA-10 ERBB4 kd cells was significantly
reduced to <25% (Fig 6B; p< 0.05). In addition, ERBB4 kd
induced marked decreases in both the average number and size of
pulmonary foci (Fig 6C and D). High ERBB4 expression in control
CHLA-10 primary implantation site tumours was confirmed by
immunohistochemistry (IHC), and a dramatic reduction of ERBB4
protein expression was seen in CHLA-10 ERBB4 kd implantation
site tumours (Fig 7A, upper panels). Interestingly, both CHLA-10
control and ERBB4 kd lung metastases displayed strong ERBB4
immunoreactivity (Fig 7A, lower panels), suggesting that in the
ERBB4 kd group, metastatic tumours formed from cells that
escaped ERBB4 knockdown or re-expressed ERBB4 following
shRNA silencing.
We then performed the converse experiment by implanting
vector control or ERBB4 overexpressing CHLA-9 cells using the
SCI model. Both cell lines formed large tumours at primary
implantation sites, although CHLA-9 vector control tumours
showed marked necrosis (Supporting Information Fig S5B).
However, whereas CHLA-9 control cells showed pushing
borders into adjacent normal kidney similar to CHLA-10 ERBB4
kd cells (Fig 6E, arrowheads), remarkably, implanted CHLA-9/
ERBB4 cells grew with a highly infiltrative pattern similar to
CHLA-10 control cells (Fig 6E, arrows), clearly demonstrating
that ERBB4 induces an invasive phenotype in vivo. Notably,
ERBB4 overexpression significantly increased the proportion of
mice with lung metastases from 22 to >60% (Fig 6F; p< 0.05),
and strikingly increased the average number and size of metastatic
tumours (Fig 6G and H). Reduced ERBB4 expression wasEMBO Mol Med (2013) 5, 1087–1102 confirmed by IHC in CHLA-9 control implantation site tumours
compared to strong ERBB4 immunostaining in both CHLA-9/
ERBB4 implantation site and metastatic tumours (Fig 7B).
To evaluate ERBB4 downstream signalling in vivo, we
compared Akt, FAK and Rac1 activity in implantation site
tumours isolated from mice implanted with CHLA-10 control
versus CHLA-10 ERBB4 kd cells. In tumours isolated from each
of three separate mice, ERBB4 kd led to almost complete
abrogation of Akt phosphorylation and significantly reduced
Rac1 (Fig 7C; p< 0.05), and FAK activation (Fig 7D; p< 0.05).
This clearly demonstrates that ERBB4 regulates Akt, FAK and
Rac1 activation in vivo. Taken together, these data strongly
support an in vivo role for ERBB4 in facilitating increased
metastatic capacity in ES.
ERBB4 expression is increased in metastatic ES tumours and
correlates with disease progression
Given that ERBB4 suppresses anoikis and increases migration
and invasion of ES cells in vitro, and enhances their metastatic
capacity in vivo, we wondered whether ERBB4 expression
correlates with metastatic disease in ES patients. We analyzed a
cohort of 19 paired biopsies of primary and metastatic ES
tumours from the same patients, as well as a tissue microarray
(TMA) containing a further 94 (78 primary and 16 metastatic)
non-paired ES tumours. IHC was used to assess ERBB4 protein
expression as described (Kang et al, 2007). Patient character-
istics are summarized in Supporting Information Table S3.
ERBB4 quantification showed significantly higher ERBB4
expression in metastatic lesions versus patient-matched primary
tumours (Fig 8A–C; p< 0.05), with 78.9% of patients having
high (strong/moderate) ERBB4 expression in metastatic lesions
compared to 42.1% in the primary tumours (Fig 8B; p< 0.05).
The TMA revealed a significantly greater percentage of cases
with high ERBB4 expression in the metastases compared to
primary tumours (81.3% vs. 57.7%, respectively; Fig 8D;
p< 0.05). In 48 patients with available demographic data, high
ERBB4 was not associated with clinic-pathological variables
such as age, gender or primary tumour site, nor with ERBB4
nuclear, cytosolic or membranous localization (Supporting
Information Table S4). Kaplan–Meier survival analysis demon-
strated a direct correlation between high ERBB4 expression and
poor outcome in ES patients (Fig 8E; p< 0.05). The median
disease-free survival time for patients with high ERBB4 levels
was 12.2 months, whereas the corresponding time for patients
with low ERBB4 immunoreactivity was 30.9 months (Fig 8E,
p< 0.05). These findings confirm a link between high ERBB4
expression and metastatic disease in ES patient samples.DISCUSSION
Outcomes for ES patients with metastatic disease have not
changed significantly in the past two decades, and the majority
of these patients die of their disease even with current multi-
modality therapy. With the goal of identifying candidate
proteins or pathways involved in ES progression, we found
that ERBB4 is transcriptionally induced in ES tumour cell lines2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 1095
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Figure 6. ERBB4 contributes to invasion and metastasis formation in vivo.
A,E. Side-by-side view of low power H&E stained primary tumours from CHLA-10 and CHLA-10 ERBB4 kd (A), and CHLA-9 and CHLA-9/ERBB4 (E) implanted mice.
Arrows in A and E point to highly infiltrative borders with direct invasion into adjacent normal kidney, whereas arrowheads point to the so-called ‘‘pushing’’
non-invasive borders.
B,F. The percentage of animals from each of these groups harbouring metastatic lesions was quantified (n¼ 8 animals/condition; p<0.05).
C,G. Representative H&E stained images of: (C) CHLA-10 and CHLA-10 ERBB4 kd, and (G) CHLA-9 and CHLA-9/ERBB4 pulmonary metastasis are shown.
D,H. The number and size of lung metastatic lesions from each of these groups were quantified; p< 0.05.
1096derived from chemoresistant or metastatic ES tumours, and that
ERBB4 protein expression is elevated when ES cell lines are
subjected to diverse stresses such as detachment from the
extracellular matrix or serum deprivation. Furthermore, ERBB4
is overexpressed in metastatic compared to primary lesions in
TMAs of ES tumours. ERBB4 overexpression activates a novel
ERBB4-PI3K-Akt-FAK-Rac1 pathway that stimulates migration
and invasion of ES cells, and confers metastatic capacity in vivo. 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.A recent study reported ERBB4 upregulation in neuroblastoma
cells in vitro under anchorage independent or serum starvation
conditions, which was also associated with marked chemore-
sistance (Hua et al, 2012) Therefore, while epithelial malig-
nancies utilize EGFR and HER2 for oncogenic signalling through
ErbB family RTKs, tumours of neural or mesenchymal origin
may instead preferentially activate ERBB4, although additional
studies are necessary to rigorously test this possibility.EMBO Mol Med (2013) 5, 1087–1102
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Figure 7. ERBB4 regulates Akt, Rac1 and FAK activation in vivo.
A,B. Representative images of IHC staining for ERBB4 in primary tumours (upper panels), or metastatic lesions (lower panels) of CHLA-10, CHLA-10 ERBB4kd,
CHLA-9 or CHLA-9/ERBB4 tumours are shown.
C. GTP-bound Rac1 levels were evaluated by pull-down assays in tumours from CHLA-10 and CHLA-10 ERBB4 kd mice; n¼3 mice per condition. Total Rac1,
ERBB4 and p-Akt Ser-473 were additionally evaluated by immunoblotting. Graph represents Rac1 activity SEM; n¼ 3, p<0.05.
D. Lysates were immunoprecipitated for endogenous FAK, and immunoblotted with p-Tyr or FAK Abs. An isotype-matched antibody was used as a negative
control. Graph represents FAK activity SEM; n¼ 3, p<0.05.The role of ERBB4 in cancer remains controversial, with
evidence for both oncogenic (Junttila et al, 2005; Prickett et al,
2009) and tumour suppressor activities (Das et al, 2010; Sartor
et al, 2001). One possible explanation for this apparent
dichotomy is that ERBB4 exists in four alternatively spliced
isoforms, suggesting divergent activity of the different isoforms
(Veikkolainen et al, 2011). Differences in the extracellular
juxtamembrane (JM) domain encoding sequences arise fromEMBO Mol Med (2013) 5, 1087–1102 inclusion of exon 15 (JM-b) versus exon 16 (JM-a) in the mature
transcript. The resulting JM-a isoform, but not JM-b, can be
cleaved by the TACE protease and subsequently by a second
protease, g-secretase (Ni et al, 2001). This generates an 80 kDa
active protein kinase that translocates to the nucleus to regulate
differentiation through STAT5 signalling (Lee et al, 2002; Rio
et al, 2000), and nuclear localization of this soluble intracellular
domain is associated with poor survival in breast cancer models2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 1097
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Figure 8. ERBB4 expression is elevated in metastatic tumour samples and correlates with disease progression in ES.
A. IHC was used to examined ERBB4 expression in 19 matched biopsies (primary tumours and metastatic sites) from the same patients; p<0.05.
B. The graph shows the percentage of ES patients displaying weak/absent versus strong/moderate ERBB4 expression in localized versus metastatic lesions;
n¼ 19; p< 0.05.
C. Representative IHC images depicting ERBB4 staining in matched primary and the corresponding distant metastasis from two ES patients are shown. Scale
bars¼50mm.
D. ERBB4 immunoreactivity was analyzed by IHC in a TMA containing n¼ 94 clinical samples. High ERBB4 expression in the metastatic lesions was found in
81.3% patients versus 57.7% patients in the primary sites; p<0.05.
E. Kaplan–Meier illustrating disease-free survival of ES patients, classified according to ERBB4 protein expression. Data show a significantly worse clinical
outcome (p< 0.05) associated with high ERBB4 expression levels.
1098  2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. EMBO Mol Med (2013) 5, 1087–1102
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Ariadna Mendoza-Naranjo et al.(Junttila et al, 2005). However, we did not detect evidence for
nuclear ERBB4 protein accumulation in high ERBB4-expressing
ES cells, even after treatment with PMA, which activates TACE
(Zhang et al, 2001). Moreover, nuclear ERBB4 expression in
clinical samples did not correlate with Ewing patient survival.
Another ERBB4 isoform pair derives from differences in the
cytoplasmic domain, based on the presence or absence of exon
26 in the coding sequence, designated as CYT-1 and CYT-2,
respectively (Elenius et al, 1999). CYT-1, but not CYT-2,
contains a PI3K binding motif, which is required for PI3K-Akt
activation by ERBB4. CYT-1 is known to regulate cell survival
and protein synthesis (Elenius et al, 1999), and its expression
mediates resistance to nutrient deprivation in medulloblastoma
(Ferretti et al, 2006). JM-a/CYT-1 and JM-a/CYT-2 were the only
ERBB4 isoforms detected in ES cells; each were enhanced in
metastatic/chemoresistant lines and further upregulated in
anchorage independent cultures. Hence, CYT-1 upregulation
may contribute to PI3K-Akt hyperactivation and cell survival
observed under non-adherent conditions and serum starvation
in ES cells. Binding of ERBB4 to its ligands has been linked to
oncogenic activity in tumours including breast cancer (Mill et al,
2011). Our data using ligand stimulation suggest that ERBB4
may already be maximally activated under S conditions, such
that additional ectopic ligand treatment is unlikely to further
increase ERBB4 tyrosine phosphorylation and activation.
Further experiments are necessary to determine if ERBB4
activation is ligand dependent or independent in ES cells.
Genome-wide copy number analysis did not reveal ERBB4 copy-
number aberrations in any of the cell lines with ERBB4
overexpression, nor were ERBB4 mutations detected. Therefore
the mechanism of ERBB4 transcriptional induction remains
unknown. ERBB4 promoter methylation is one possibility, and
we are exploring this experimentally. It is also interesting to note
that the three ES cell lines with the lowest basal ERBB4
expression levels were also those with functional p53 status
(Supporting Information Table S2), and so it will be important to
determine if there is a link between p53 inactivation and stress-
induced ERBB4 induction.
Our findings point to potential predictive value of ERBB4
overexpression as a biomarker for metastatic disease in ES.
Although previous studies have shown associations between
ERBB4 expression and different human cancers (Ferretti et al,
2006; Frey et al, 2010; Junttila et al, 2005; Kang et al, 2007;
Maatta et al, 2006; Mill et al, 2011; Sartor et al, 2001), to date no
links with tumour metastasis have been reported. Forced ERBB4
overexpression in non-metastatic CHLA-9 ES cells led to a highly
infiltrative growth pattern into surrounding kidney tissue after
renal SCI, similar to what was observed for implanted CHLA-10
cells, which high basal ERBB4 expression. Infiltrative borders
were strongly associated with increased pulmonary metastasis.
Conversely, ERBB4 kd completely blocked this phenomenon in
CHLA-10 cells, and reverted the phenotype to the non-invasive
well-demarcated borders of implanted control CHLA-9 cells,
characteristic of cells of limited metastatic potential (Zlobec
et al, 2009). These studies demonstrate that ERBB4 expression
by itself is sufficient to promote invasive and metastatic
potential in ES.EMBO Mol Med (2013) 5, 1087–1102 The signalling pathways underlying progression and acquisi-
tion of the metastatic phenotype are largely unknown. ERBB4
activation markedly activated Rac1, which has well-established
links to cytoskeletal dynamics and cell migration, and which
is implicated in cancer cell invasion and metastasis (Parri &
Chiarugi, 2010). ERBB4-mediated Rac1 activation in ES cells
was regulated through both PI3K and FAK, as inhibition of each
significantly impaired Rac1 activity as well as migration and
invasion. PI3K, which interacts directly with and is regulated by
ERBB4 (Elenius et al, 1999), is required for Rac1 activation
(Vega & Ridley, 2008), and PI3K activation supports metastasis
in many tumour types (Ni et al, 2001). FAK is required for EGF-
induced cell migration, and is a key integrator of RTK and
integrin signalling pathways to regulate cell motility (Sieg et al,
2000). Moreover, FAK has been linked to the invasive
phenotype of tumours in a kinase and Rac1-dependent manner
(Hsia et al, 2003). We found that ERBB4 kd blocks Tyr-397
phosphorylation, the major autophosphorylation site of FAK
(Schaller et al, 1994), as well as overall FAK activation under cell
spreading conditions, an early step in tumour cell migration and
invasion (Timar et al, 1996). However, inhibition of PI3K had no
apparent effects on FAK activation, and blocking FAK only
partially reduced Akt phosphorylation. This suggests that
ERBB4 activates FAK upstream of PI3K-Akt, and that ERBB4
can activate PI3K through both FAK-dependent and indepen-
dent mechanisms. Since ERBB4 kd blocks both FAK and
PI3K-Akt, and inhibition of each pathway impairs migration and
invasion, our findings point to a dual role for these proteins in
ERBB4-mediated migration and invasion of ES cells.
In summary, our results highlight ERBB4 as a marker of
metastatic or relapsed ES. We demonstrated moderate decreases
in ERBB4 activity by treatment with Lapatinib, a pan-ERBB
inhibitor previously used to target ERBB4 in melanoma (Prickett
et al, 2009). This provides preliminary evidence that therapeutic
inhibition of ERBB4, such as through new generation ERBB4
inhibitors, may be a tractable strategy for the prevention or
treatment of metastatic ES.MATERIALS AND METHODS
Cell lines and antibodies
TC71, TC32, TTC 446 and TC135 ES cells lines were purchased from
American Type Culture Collection. SK-N-MC, COG-E-352, ES-5838
and CHLA-25 cell lines were contributed by one of the co-authors,
TJT. The human ES cell lines CHLA-9, CHLA-10, CHLA-258 were
established as described (Batra et al, 2004). Biological characteristics
and culture conditions for each cell line are summarized in Supporting
Information Table S2.
ERBB4 immunoblotting and immunoprecipitation
ERBB4 tyrosine phosphorylation was assessed in CHLA-10 cells grown
as M or S, and treated with 1mM Lapatinib for 24 h. Cells were lysed
and immunoprecipitation was performed as previously described
(Kang et al, 2007), using an anti-ERBB4 Ab (Santa Cruz Biotechnol-
ogy). Samples were immunoblotted with anti-phosphotyrosine (p-Tyr)
and ERBB4 Abs (Cell Signaling). Detailed descriptions and dilutions of2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 1099
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The paper explained
PROBLEM:
Ewing sarcoma (ES) is the second most common bone tumour in
children and adolescents. Most ES-related deaths occur due to
metastatic disease, and these patients have 5-year survival rates of
only 20–25%.Hence, there is anurgent need to identify thebiological
drivers of metastasis in ES and to develop novel therapeutics that
will specifically prevent or target metastases in these patients.
RESULTS:
There are very few reports relating to molecular mediators of
metastasis in ES. Here, we show that overexpression of ERBB4,
a member of the epidermal growth factor receptor family, is
directly linked to metastasis in ES, as inhibition of ERBB4 reduces
metastasis formation of ES cells.
IMPACT:
Our finding that ERBB4 overexpression is directly linked to in vivo
metastasis predicts that therapeutic targeting of ERBB4, alone or
in combination with cytotoxic agents, could block or target the
metastatic potential of ES.
1100all antibodies used in this study are provided in Supporting
Information Table S5.
ERBB4 knockdown experiments
Packaging HEK-293T cells were transfected with p8.91 (gag-pol
expressor), pMDG (VSV-G expressor) and a lentiviral construct (either
scrambled or two different ERBB4 shRNAs clones) at a ratio of 1:1:1.5
using Opti-MEM (Gibco) and 1nM polyethyelnimine (PEI; Polysciences).
The transfection media was replaced by culture media after 16h
incubation, and viral supernatants were harvested 24, 48 and 72h later
and supplemented with 5mg/ml polybrene (Sigma-Aldrich) before been
filtered and stored at 808C. ERBB4 shRNAs clones TRCN0000001410
and TRCN0000001411 (ccggcctgtggctattaagattcttctcgagaagaatcttaat
agccacaggttttt and ccgggcgcaggaaacatctatattactcgagtaatata-
gatgtttcctgcgcttttt, respectively) were from Thermo Scientific Open-
Biosystems, and were designated 1410 and 1411. A non-silencing-GIPZ
lentiviral shRNAmir construct, herein designated Scrambled was used as
a control (catalogue RHS4346, Thermo Scientific Openbiosystems).
CHLA-9, CHLA-10, CHLA-25, CHLA-258 and SK-N-MC ES cells were
transduced with lentiviral particles containing shRNA constructs
encoding the ERBB4 shRNA and scrambled sequences and were selected
with puromycin-containing media (1mM; Sigma Aldrich), added every
2 days for 1 week before being plated for experiments.
Rac1 and Cdc42 Rho GTPase activation assays
Rac1 and Cdc42 GTPase activities were assessed as previously
described (Mendoza-Naranjo et al, 2012), in CHLA-9, CHLA-9 cells
overexpressing ERBB4, CHLA-10 and ERBB4 shRNA CHLA-10 cells
plated for 2 h (cell spreading conditions), or growth as M or S for 24 h.
In some experiments, CHLA-10 cells were pre-treated for 16 h with
5mM UO126 (BD Biosciences), 10mM LY294002 (BD Biosciences),
1mM FAK inhibitor II (Calbiochem) or 5mM FAK inhibitor 14 (Tocris
Bioscience) before been plated for 2 h for cell spreading assays, or 24 h
under anchorage-independent conditions. Treatments with the
inhibitors were kept during those experiments. Rac1 activity was
also measured in implantation site tumours isolated from mice
implanted with CHLA-10 control or CHLA-10 ERBB4 kd cells (three
mice per condition), carefully dissected free of stroma and normal
kidney tissue. 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.Renal subcapsular implantation (SCI) mouse model
Male, 7-week-old NOD-SCID mice from the Animal Resource Centre
BCCRC were maintained according to UBC Animal Care Committee
(ACC) regulations. Briefly, cell blocks containing 1106 CHLA-9 pLEOC
control, CHLA-9/ERBB4, CHLA-10 Scrambled or CHLA-10 ERBB4 kd ES
cell lines were mixed in 50ml DMEM-rat tail collagen gel, seeded in
cell culture plates, incubated for 30min and then implanted under the
capsules of exteriorized kidneys of anaesthetized live NOD-SCID mice;
n¼8 mice per condition. The kidneys were then gently eased back into
the body cavity, the incisions were sutured and the mice were
monitored for tumour growth for 7 weeks, in the case of CHLA-10
cells, and 12 weeks for CHLA-9 cells.
Statistical analysis
Statistical differences were determined using Wilcoxon matched-pairs
signed-ranks test for paired data, or analyzed by Bonferroni–Holm post
hoc test after one-way analysis of variance (ANOVA) for data sets of
multiple comparisons. All data are presented as the mean SD except
where stated. Criterion levels for the individual tests are given in the
Results section. Kaplan–Meier curves and the log-rank test were used to
estimate and compare disease-free survival in ES patients. The association
between diagnostic clinico-pathological variables and ERBB4 expression
was evaluated using the Fisher’s exact test. The significance level was set
at 5%. Itemized numerical p-values and the statistical tests used to
generate each p-values for all of the experimental conditions analyzed in
the manuscript figures are itemized in Supporting Information Table S6.Author contributions
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